Sana Biotechnology Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while Vanguard Information Technology Index Fund ETF trades at $120.77. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VGT | |
|---|---|---|
Market Cap | $1.03B | — |
Sector | Health | — |
52-Week High | $5.92 | $125.77 |
52-Week Low | $2.68 | $83.59 |
Enterprise Value | $946.04M | — |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VGT trades at $121.05, down slightly by 0.18% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds a strong position in technology stocks, with recent institutional buying indicating confidence. Key support sits at $119, while resistance is at $122.
The outlook remains positive due to technology sector growth and AI exposure, but risks include high concentration in semiconductor stocks and market volatility. Long-term potential is supported by innovation trends, though investors should monitor sector-specific headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →